Adverse Drug Events – Reporting & Regulatory Requirements™

• Adverse Event (AE) Terminology
• Role & responsibilities of Pharma and the Regulatory Agency in AE reporting 
• Pre & Post-marketing AE reporting requirements worldwide
• Product Safety Update Reports
• Pharmacovigilance
• Safety issues
• Coding

This course will provide participants with an understanding of drug safety at the investigational stage and during the marketing phase. Adverse event identification and reporting requirements will be addressed, as well as FDA, EMEA, Health Canada and ICH roles in the drug safety process. The course will also discuss international law/regulations, ICH guidelines, Pharmacovigilance, definitions and current regulatory issues. 

Adverse Event reporting requirements specific to the US, Canada, Japan, and Europe will be discussed and compared in detail.  Participants will be provided with templates for reporting requirements in each region covered.

Multiple exercises are included to reinforce the lecture material.  Through the use of various scenarios, participants will learn how to assess and report AEs including SAEs

“Very informative – gained valuable understanding of ADE reporting history.” 
Susan W., Sr. Product Support Specialist, Pfizer

“I like the Course Director's process of having exercises after each module to review the basic topics covered in that module.  He also easily refers back to the regulations when questions are asked.  I highly recommend this course...the best Adverse Events training available!” 
Marissa F., Manager, Vasogen

“I highly recommend this class to anyone who is involved in clinical research and operation in the investigator sites and sponsor sites, as well as health professionals.  Thank you so much and I am looking forward to taking other classes you offer in the future!” 
Ge Z., MD, PhD, Manager of Clinical Development, Siemens Medical Solutions USA